Objective: To use multiple serial MRI to assess rates and trajectories of brain and hippocampal atrophy in subjects with frontotemporal dementia (FTD) with progranulin (GRN) or microtubuleassociated protein tau (MAPT) gene mutations.
Frontotemporal dementia (FTD) is a progressive neurodegenerative disease associated with brain atrophy. 1, 2 Rate of atrophy is an excellent disease biomarker that is already used as an outcome measure in treatment trials for neurodegenerative disorders other than FTD, since clinical trial data for FTD are sparse. Subjects with genetic mutations are ideal candidates for treatment trials in FTD since we can infer the underlying pathology. The 2 most commonly mutated genes in FTD are microtubule-associated protein tau (MAPT) and progranulin (GRN), with MAPT mutations associated with tau pathology and GRN mutations associated with TDP-43 pathology. Determining rate of atrophy in these 2 mutations, and understanding the natural biology of how brain volume changes over time, will be critical if rates of atrophy are to be utilized as outcome measures in future treatment trials using these subjects.
The aim of this study was to assess rates and trajectories of whole brain and hippocampal atrophy throughout the disease course in subjects with these mutations. Given the variability in age at onset and large differences between GRN and MAPT mutations, 3 we also assessed whether rate of atrophy is associated with age.
METHODS Subjects. We identified all subjects from Mayo Clinic, MN, between January 1992 and January 2011 who had screened positive for mutations in GRN or MAPT and had at least 2 MRIs. All subjects were followed prospectively with annual clinical examinations. Eight GRN subjects (5 families) were identified, with 5 mutations: 4 subjects with the c.154delA(p.Thr52HisfsX2) mutation, and one subject each with mutations c.1477CϾT(p.Arg493X), c.102delC(p.Gly35GlufsX19), c.1145delC(p.Thr382SerfsX30), and c.138 ϩ 1GϾA(IVS1 ϩ 1GϾA p.Met). Twelve MAPT subjects (9 families) were identified, with 6 mutations: 4 subjects with P301L [c.1907CϾT(p.Pro301Leu)], 2 subjects with S305N [c.1919GϾA (p.Ser305Asn)], 2 subjects with 10 ϩ 3 [c.1920 ϩ 3GϾA (IVS10 ϩ 3GϾA)], 2 subjects with 10 ϩ 16 [c.1920 ϩ 16CϾT(IVS10 ϩ 16CϾT)], and one subject each with N279K [c.1842TϾG(p.Asn279Lys)] and G389R [c.2170GϾA(p.Gly389Arg)] mutations. Six GRN and 2 MAPT subjects came to autopsy showing TDP-43 immunoreactive inclusions in the former group, and widespread tau deposition in the later. Detailed clinical data have been previously reported in these cases. 4, 5 The GRN and MAPT groups were each matched to a healthy control cohort by age, gender, number of MRI, and time from first to last MRI. Subject demographics are shown in the table.
Standard protocol approvals. Informed consent was obtained from all subjects for participation in the studies, which were approved by the Mayo institutional review board. MRI analysis. All MRI were acquired using standardized imaging protocols. Thirteen subjects were scanned at 1.5 T, 4 subjects at 3 T, and 3 subjects had early scans performed at 1.5 T and later scans performed at 3 T. All MRI underwent prepro-cessing correction for gradient nonlinearity and intensity nonuniformity. To generate whole brain data, serial MRI were registered to baseline for each subject using 9 df registration. All registrations were performed across scan pairs performed at the same field strength. Hence, 3 T scans were registered to the first available 3 T scan. Change in brain volume was calculated from registered scan pairs using the boundary-shift integral (BSI). 6 The BSI results between each interval were used to calculate brain volume at each timepoint. Hippocampal and total intracranial volume (TIV) were calculated for each timepoint using the Freesurfer software (version 4.5.0) 7 longitudinal pipeline. Freesurfer processing was only performed on batches of serial scans performed at the same field strength.
Statistics.
Mixed-effects linear regression models using disease duration at baseline as the time scale were used to estimate change in brain volume over time among MAPT and GRN subjects. Random kindred and subject-within-kindred intercepts and slopes were included. Fixed effects of primary interest were disease duration, genotype, and a disease duration-by-genotype interaction. The model also included fixed effects for field strength, TIV, and age at baseline MRI. Together, these fixed effects allow brain volume to decline linearly with disease duration with possibly different rates of decline by genotype. We modeled the log of brain volume to estimate rate of volume loss expressed as percentage per year. To evaluate the effect of age separately within genotype, we fitted a model that included a 3-way interaction between genotype, disease duration, and age at baseline MRI. We used a similar approach to compare cases to their respective control groups but omitted kindred from the models and by necessity treated time from baseline MRI as the timescale. Because subject measurements were observed to be approximately linear over the observed time period and because of the few subjects, in order to protect against overfitting, we made the simplifying assumption of linear withinsubject trajectories.
RESULTS
The annual rate of whole brain atrophy was higher in both GRN and MAPT compared to controls ( p Ͻ 0.001 for both), with rates higher in GRN compared to MAPT ( p ϭ 0.01) (table and fig Rates of whole brain atrophy in the GRN group differed according to age ( p ϭ 0.01), with older subjects showing slower rates of atrophy (i.e., rates at age 60 ϭ 3.7%/year, 65 ϭ 2.9%, and 70 ϭ 2.1%/year) ( figure 1) . In contrast, rates of hippocampal atrophy in the MAPT group differed according to age ( p Ͻ 0.001), with older subjects showing slower rates of atrophy (i.e., rates at age 35 ϭ 13.6%/year, 45 ϭ 8.6%/year, and 55 ϭ 3.6%/year) (figure 2). No effect of age was observed on rates of hippocampal atrophy in GRN ( p ϭ 0.86) and whole brain atrophy in MAPT ( p ϭ 0.57).
DISCUSSION
Using multiple serial MRI scans and mixed effects modeling, we demonstrated that subjects with GRN mutations have a faster trajectory of whole brain atrophy than subjects with MAPT mutations, suggesting a more rapidly progressing disease course in GRN. One other small study that assessed rates of atrophy using only 2 MRI scans per subject similarly found faster rates of atrophy in GRN. 8 Our finding is also in keeping with another study that demonstrated faster rates of functional decline in GRN compared to MAPT. 9 Rates of hippocampal atrophy were similar, however, across the mutations. Interestingly, the ratio of hippocampal to whole brain atrophy was greater in MAPT (3:1) than GRN (2:1), suggesting disproportionate involvement of the hippocampus in MAPT. Indeed, anteromedial temporal atrophy is a feature of MAPT mutations. 10 In addition, rates of atrophy in GRN and MAPT were associated with age. In GRN, rates of whole brain atrophy were faster in younger than older subjects, and in MAPT, rates of hippocampal atrophy were faster in younger than older subjects. These findings may reflect the anatomic signatures of these mutations. Mutations in GRN are associated with widespread cerebral atrophy and so may be better represented by a whole brain measure of atrophy, whereas MAPT mutations are associated with anteromedial temporal atrophy which may be better represented by hippocampal measures. Since the MAPT subjects were younger than the GRN subjects, as previously reported, 3,5 yet had slower rates of whole brain atrophy, our findings suggest that the age effect occurs within each mutation group and not across all subjects with genetic mutations.
Based on our models, we found a significant fieldstrength effect ( p ϭ 0.003) with 3 T scans showing larger volume estimates. However, we accounted for these differences in our analysis and found that field strength was not associated with group ( p ϭ 0.78). The number of serial MRIs was lower in the GRN group, which could have reduced power, although we were still able to identify a significant age effect in this group. These findings highlight important differences across GRN and MAPT subjects which will be important for future treatment trials that employ rates of atrophy as biomarkers.
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